CompletedPhase 2/3

Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

Egypt100 participantsStarted 2021-10-01

Plain-language summary

Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart failure. However, it is still unknown if their role extent into preventing heart failure, especially after acute myocardial infarction. This study aimed at identifying if there is such role for SGLT2i.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with Diabetes Miletus (Type 1 (DMT2), Type 1 (DMT1), secondary diabetes (e.g., endocrinopathies)
✕. Patients already diagnosed with heart failure prior to this event
✕. Patients on cardiotoxic chemotherapeutic medications.
✕. Patients with haemoglobinopathies.
✕. Patients with chronic organ damage (i.e., chronic hepatitis with MELD score \>10, Stage 4 \& 5 renal disease).
✕. Patients already on SGLT2i.
✕. Patients who will require additional anticoagulant therapy (i.e.: patients with transthoracic echocardiographic evidence of left ventricular thrombus).
✕. Patients with contraindications for use of dapagliflozin including patients with severely impaired renal function (eGFR \<30ml/min/1.73m2) \&/OR previous history of genitourinary infections (i.e.: urosepsis, pyelonephritis \& fournier's gangrene) \&/OR at high risk of such infections.

What they're measuring

A change in NT-proBNP levels from baseline to 12 weeks post-anterior STEMI

Timeframe: 12 weeks

A change in left ventricular ejection fraction, end-diastolic volume or left ventricular mass index assessed by transthoracic echocardiography at baseline, 4 weeks & 12 weeks post-anterior STEMI

Timeframe: 12 weeks

Trial details

NCT IDNCT05424315

SponsorOmar Younis

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2022-04-30

View on ClinicalTrials.gov More Anterior MI trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with Diabetes Miletus (Type 1 (DMT2), Type 1 (DMT1), secondary diabetes (e.g., endocrinopathies)
✕. Patients already diagnosed with heart failure prior to this event
✕. Patients on cardiotoxic chemotherapeutic medications.
✕. Patients with haemoglobinopathies.
✕. Patients with chronic organ damage (i.e., chronic hepatitis with MELD score \>10, Stage 4 \& 5 renal disease).
✕. Patients already on SGLT2i.
✕. Patients who will require additional anticoagulant therapy (i.e.: patients with transthoracic echocardiographic evidence of left ventricular thrombus).
✕. Patients with contraindications for use of dapagliflozin including patients with severely impaired renal function (eGFR \<30ml/min/1.73m2) \&/OR previous history of genitourinary infections (i.e.: urosepsis, pyelonephritis \& fournier's gangrene) \&/OR at high risk of such infections.

What they're measuring

A change in NT-proBNP levels from baseline to 12 weeks post-anterior STEMI

Timeframe: 12 weeks

A change in left ventricular ejection fraction, end-diastolic volume or left ventricular mass index assessed by transthoracic echocardiography at baseline, 4 weeks & 12 weeks post-anterior STEMI

Timeframe: 12 weeks